Patient with multiple metastases, not eligible for surgery, might not profit from intensive
chemotherapy regimens. Therefore less intensive regimens focusing on survival and disease
control may be a better choice for first line treatment. Therefore this study investigates
the combination of capecitabine and bevacizumab versus the combination of capecitabine,
bevacizumab and irinotecan. In case of progressive disease, the therapy in patients treated
with capecitabine and bevacizumab is intensified by adding irinotecan. Primary endpoint is
time-of-failure strategy (TFS) comparing both treatment arms.